

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

2022 FIRST QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the first quarterly report of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) for financial year 2022 (the “**2022 First Quarterly Report**”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises or the International Financial Reporting Standards issued by the International Accounting Standards Board (the “**IFRSs**”) (as applicable) and has not been audited.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, April 25, 2022

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purpose only*

I. Important Notice

- 1.1 The Board, the Supervisory Committee and the Directors, the supervisors and the senior management of the Company warrant the truthfulness, accuracy and completeness of the contents of the 2022 First Quarterly Report and that there are no false information, misleading statements or material omissions in the 2022 First Quarterly Report, and shall assume several and joint legal responsibilities.
- 1.2 Ge Li, the person in charge of the Company, Ming Shi, the chief financial officer and Jin Sun, the director of the accounting department (person in charge of accounting) warrant the truthfulness, accuracy and completeness of the financial statements contained in the 2022 First Quarterly Report.
- 1.3 The 2022 First Quarterly Report of the Company has not been audited.
- 1.4 Definitions

Definitions of frequently-used terms

“A Share(s)”	domestic shares of the Company, with a nominal value of RMB1.00 each, which are listed for trading on the Shanghai Stock Exchange and traded in RMB
“Board”	the board of directors of the Company
“China” or “PRC”	the People’s Republic of China, which for the purpose of this quarterly report and for geographical reference only excludes the Hong Kong Special Administrative Region of the PRC, the Macao Special Administrative Region of the PRC and Taiwan
“clinical trial(s)”	systematical investigation of drugs conducted on human subjects (patients or healthy volunteers) to prove or reveal the function, adverse reactions and/or absorption, distribution, metabolism and excretion of the drug being investigated. The purpose of a clinical trial is to determine the therapeutic efficacy and safety of the drug
“CRDMO”	Contract Research Development and Manufacturing Organization

“CRO”	Contract Research Organization, an academic or commercial scientific organization which provides professional services for drug research of pharmaceutical enterprises and research and development organizations on a contract basis
“CTDMO”	Contract Testing Development and Manufacturing Organization
“Director(s)”	the director(s) of the Company
“end of the Reporting Period”	March 31, 2022
“H Share(s)”	overseas listed foreign shares in the share capital of the Company with nominal value of RMB1.00 each, which are listed on the Stock Exchange
“IFRSs”	International Financial Reporting Standards issued by the International Accounting Standards Board
“IND filing”	filing for clinical trial of investigational new drug (IND), which is necessary before commencement of clinical trial
“Reporting Period”	the period from January 1, 2022 to March 31, 2022
“RMB” or “RMB million”	Renminbi yuan or million yuan
“Share(s)”	ordinary shares in the capital of the Company with a nominal value of RMB1.00 each, comprising A Shares and H Shares
“SMO”	Site Management Organization for clinical trials
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Supervisory Committee”	the supervisory committee of the Company
“U.S.”	the United States of America, its territories, its possession and all areas subject to its jurisdiction
“WIND”	WuXi IND service platform

II. Company Profile

The Company provides the global healthcare industry with integrated end-to-end new drug discovery, development and manufacturing services, with operation bases in Asia, Europe and North America. The Company continuously lowers the entry barrier of R&D through its unique CRDMO and CTDMO business models, helps customers increase their R&D efficiency and delivers groundbreaking treatment solutions to patients. Our services cover CRDMO of chemical drugs, biology research, pre-clinical testing and clinical trial, CTDMO of cell and gene therapy, and other areas. As at the end of the Reporting Period, the Company provided services to over 5,800 active customers in over 30 countries through its 31 operating bases and subsidiaries worldwide. As at the end of the Reporting Period, the Company had 36,997 employees, including 10,968 employees with a master's or higher degree and 1,245 employees with a Ph.D. or equivalent degree. A breakdown of our employees by function and by geography is set out below:

Position	Asia	U.S.	Europe	Total
Research and development	29,022	1,014	154	30,190
Manufacturing	3,660	254	75	3,989
Sales	39	89	31	159
Management and administration	2,181	410	68	2,659
Total	<u>34,902</u>	<u>1,767</u>	<u>328</u>	<u>36,997</u>

To maintain the high service standards and industry leading expertise and continuously meet customers' demands, the Company will continue to recruit, train, promote, incentivize and retain talented individuals.

III. Major financial data

1. Major financial statement items and financial indicators

Unit: RMB

Item	For the Reporting Period		Year-over-year increase/decrease (%)
	As at the end of the Reporting Period	As at the end of the previous year	Increase/decrease of the end of the Reporting Period as compared to the end of the previous year (%)
Revenue	8,474,419,333.59		71.18
Net profit attributable to the owners of the Company	1,642,947,345.12		9.54
Net profit attributable to the owners of the Company after deducting non-recurring gain or loss items	1,714,144,938.66		106.52
Adjusted non-IFRS net profit attributable to the owners of the Company	2,052,645,414.94		85.82
Net cash flows from operating activities	497,469,053.50		-25.62
Basic earnings per share (RMB/share)	0.56		7.69
Diluted earnings per share (RMB/share)	0.53		3.92
Weighted average return on net assets (%)	4.16		decreased by 0.27 percentage points
Total assets	57,582,930,874.69	55,127,388,384.03	4.45
Equity attributable to the owners of the Company	40,364,486,821.13	38,491,509,630.60	4.87

2. Non-recurring gain or loss items and amounts

Unit: RMB

Item	Amount for the Reporting Period	Description
Gain or loss on disposal of non-current assets	-4,555,683.27	
Government grants included in profit or loss of the current period, except for those closely related to the Company's normal operation and which were granted on a recurring basis subject to certain amount or volume upon fulfilment of specific standards in compliance with the government policies and regulations	58,507,543.76	
Gain or loss arising from changes in fair value of holding held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities and derivative financial liabilities, and investment income from disposal of held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities and derivative financial liabilities and other equity investments, except effective hedging business related to the Company's normal operations.	-91,674,803.89	From January to March 2022, mainly include: a gain of RMB141.4703 million from disposal of investments, a gain of RMB82.7947 million from fair value change in convertible bonds, and a gain of 4.4485 million from fair value changes of financial liabilities and disposal of transactional financial asset during the holding period, offset by a loss of RMB320.3883 million from fair value change on investment portfolios.
Other non-operating income and expenses other than the above items	-4,315,370.93	
Less: Effect of income tax	28,964,590.30	
Less: Impact on minority interests (after tax)	194,688.91	
Total	<u><u>-71,197,593.54</u></u>	

Explanation on classifying the non-recurring profit or loss items listed in the “Explanatory Announcement on Information Disclosure for Companies Making Public Offering of Securities No. 1 — Non-recurring Profit or Loss” as recurring profit or loss items

Applicable Not applicable

3. Significant changes in major financial statement items and financial indicators of the Company and the reasons thereof

Applicable Not applicable

Item	Change for the Reporting Period (%)	Main reasons
Revenue	71.18	Please refer to the note below for details.
Net profit attributable to the owners of the Company after deducting non-recurring gain or loss items	106.52	It was mainly due to the further improvement of capacity utilization and demonstration of the scale effect through continuous optimization of operating efficiency
Adjusted non-IFRS net profit attributable to the owners of the Company	85.82	It was mainly due to the further improvement of capacity utilization and demonstration of the scale effect through continuous optimization of operating efficiency
Net cash flows from operating activities	-25.62	It was primarily due to increase in collection of receivables while largely offset by the significant increase in material purchase payment arising from inventory preparation to meet the increased customer demands

Analysis note:

Revenue

The Group has been continuously developing its integrated and end-to-end capabilities across the businesses of research, development, manufacturing, testing and clinical trials, and has also been continuously implementing the CRDMO and CTDMO strategies of the Group, while managing the various operating segments of the Group on the basis of globalization.

Unit: Million Currency: RMB

Operating segments	First quarter of 2022	First quarter of 2021	change (%)
Chemistry business (WuXi Chemistry)	6,118.0	3,027.0	102.1
Testing business (WuXi Testing)	1,279.4	971.4	31.7
Biology business (WuXi Biology)	532.6	422.1	26.2
Cell and gene therapy CTDMO business (WuXi ATU)	298.6	218.0	37.0
Domestic Discovery Service Unit (WuXi DDSU)	240.6	306.8	-21.6
Others	5.2	5.1	1.6
Total	8,474.4	4,950.5	71.2

Note: Any discrepancies between the total shown and the sum of the amounts listed in the above table are due to rounding.

In the first quarter of 2022, our revenue grew by 71.2% year-over-year (YoY) to RMB8,474.4 million due primarily to the following:

- (1) Our chemistry business (WuXi Chemistry) realized revenue of RMB6,118.0 million in the first quarter of 2022, representing a YoY growth of 102.1% as compared to the revenue of RMB3,027.0 million in the same period of 2021. Revenue from small molecule drug discovery (R) services amounted to RMB1,744.9 million, representing a YoY growth of 46.6%, and revenue from process development and manufacturing (D&M) services amounted to RMB4,373.1 million, representing a YoY growth of 138.1%. Excluding the COVID-19 commercialization project, revenue from chemistry business recorded a YoY growth of 52.3%. We fully leveraged our technology advantage in process development and pushed forward the strategy of “follow-the-molecule”. In relation to small molecule drug discovery (R) services, we completed the synthesis of more than 90,000 custom synthesized compounds in the first quarter of 2022, empowering customers of early-stage development of innovative small molecule drugs and serving as an important “funnel entrance” of the Company’s downstream business units. By establishing close collaborative relationships with our customers in drug discovery and preclinical stages based on our “follow-the-customer” and “follow-the-molecule” strategies, we are able to seek opportunities for new projects from late clinical stage to the commercialization stage, facilitating sustainable and rapid growth in revenue from our Contract Research Development and Manufacturing Organization (CRDMO) services. The Company continuously implements the long-tail customer strategy and has recorded robust growth in long-tail customers. During the Reporting Period, we added 217 molecules to the chemistry process development and manufacturing pipeline. As at the end of the first quarter of 2022, our chemistry services involved 1,808 new drug molecules, including 49 in Phase III, 271 in Phase II, 1,446 in Phase I and preclinical stage and 42 drug approvals. In terms of D&M services of new modalities, the number of oligonucleotide and peptide D&M customers under our chemistry business sector was 86, representing a YoY growth of 72%. The number of oligonucleotide and peptide D&M molecules was 121, representing a YoY growth of 98%. Revenue from oligonucleotide and peptide D&M reached RMB251 million. WuXi Chemistry continued to accelerate the development of production capacity. During the Reporting Period, our facility in Changshu for drug substance manufacturing was put into operation, and we also began operating part of our Changzhou Phase III new GMP manufacturing facilities including a new R&D center and two plants.

- (2) Our testing business (WuXi Testing) realized revenue of RMB1,279.4 million in the first quarter of 2022, representing a YoY growth of 31.7% as compared to the revenue of RMB971.4 million in the same period of 2021. Revenue from lab analysis and testing services amounted to RMB909.1 million, representing a YoY growth of 39.9%, and revenue from clinical CRO and SMO amounted to RMB370.3 million, representing a YoY growth of 15.2%. In relation to drug analysis and testing services, the company provided a series of related services including DMPK (drug metabolism and pharmacokinetics), toxicology and bioanalytical testing. We leveraged our integrated platform through the WIND service platform, and integrated preclinical pharmacodynamics, pharmacokinetics, safety evaluation, and application writing and filing to provide a one-stop service for customers in respect of new drug R&D and filing globally so as to accelerate their process of new drug R&D. In the first quarter of 2022, 47 service contracts were signed through the WIND service platform. In respect of drug safety evaluation business, revenue maintained significant growth momentum as compared to the same period of last year and realized a YoY growth of 53% during the Reporting Period. We maintained and expanded our industry-leading position in Asia for drug safety evaluation services that meet the highest global regulatory requirements. Testing services for medical devices recovered significantly and recorded a YoY growth of 27% during the Reporting Period. In respect of clinical CRO services, in the first quarter of 2022, the Company provided clinical testing and development services to around 160 projects and assisted customers in obtaining approval for four clinical research applications. For clinical SMO services, the Company continued its rapid expansion. As at the end of the first quarter of 2022, the SMO team had more than 4,600 staff, representing a YoY growth of 26%, across over 1,000 hospitals in approximately 150 cities in China. In the first quarter of 2022, SMO supported four new drugs approval.

- (3) Our biology business (WuXi Biology) realized revenue of RMB532.6 million in the first quarter of 2022, representing a YoY growth of 26.2% as compared to the revenue of RMB422.1 million in the same period of 2021. The Company has the largest discovery biology enabling platform, with more than 2,500 experienced scientists who provide comprehensive biology services and solutions covering all stages and therapeutic areas of drug research and development. The Company has established three centers of excellence for NASH (non-alcoholic steatohepatitis), anti-viral, neuroscience and aging. The Company has a leading DNA Encoded Library (DEL) and hit compound generation platform. More than 1,100 customers globally now use our DEL services. We leverage our global network of sites in China, U.S. and Germany to develop and use new technologies such as One-Bead-One-Compound (OBOC) to drive growth and maintain business continuity. The Company continues to build new biology capabilities related to new modalities, including target protein degradation, nucleic acid based and conjugated modalities, vector platforms, and novel drug delivery vehicles. In the first quarter of 2022, revenue from new modalities and large molecules in WuXi Biology grew 110%, and its revenue contribution rose to 17.6% in the first quarter of 2022, from 14.6% in 2021, suggesting that new modalities-related biology services have become an increasingly important growth driver.
- (4) Our cell and gene therapy CTDMO business (WuXi ATU) realized revenue of RMB298.6 million in the first quarter of 2022, representing a YoY increase of 37.0% as compared to the revenue of RMB218.0 million in the same period of 2021. The Company further strengthened the capabilities in product testing, process development and production of cell and gene therapy products. It provided development and production services for 74 projects, including 59 clinical testing projects in preclinical and phase I, 7 clinical testing projects in phase II, and 8 clinical testing projects in phase III (4 projects are in BLA preparation stage). In March 2022, the Company has officially launched TESSA™ technology, which is a state-of-the-art novel technology for the scalable production of transfection-free adeno-associated virus (AAV). The latest data published in the Nature Communications supports the benefits of TESSA™ technology. It highlights that in the same manufacturing volume, TESSA™ vectors produced 10 times more AAV than plasmid-based technology. As at the end of the first quarter 2022, we have 14 TESSA™ evaluation projects.

- (5) Our Domestic Discovery Service Unit (WuXi DDSU) realized revenue of RMB240.6 million in the first quarter of 2022, representing a YoY decrease of 21.6% as compared to RMB306.8 million in the same period of 2021. The decrease in the revenue was mainly due to the upgrade of domestic new drug discovery service unit in response to the higher requirements for new drug R&D services from our customers, which has affected the results of the period to a certain extent. In the first quarter of 2022, the Company helped customers complete IND filing process for 2 projects and obtain 16 clinical trial approvals. As at the end of the first quarter of 2022, the Company had completed IND filing for 146 projects and obtained clinical trial approvals for 126 projects. In addition, new drug application (NDA) for 1 project was in progress, and there were 3 projects, 16 projects and 74 projects in Phase III, Phase II and Phase I clinical trials, respectively. Among the 146 projects that INDs were filed or currently in clinical stage, approximately 70% were among the top 3 in terms of clinical trial progress for similar drug candidates in China. Upon the commercialization of customers' products, the Company will share the revenue from customers at an agreed percentage when their products are sold, in accordance with the relevant customer agreements.

After the outbreak of Omicron in Shanghai at the end of the first quarter of 2022, we quickly implemented our business continuity plan to ensure the health of our employees whilst operating our business continuously. We effectively leveraged our global capacities and comprehensive capabilities to meet project delivery timelines and capture new business opportunities. If the Omicron outbreak in Shanghai would be largely controlled by the end of April 2022, we expect to grow our revenue by 63–65% YoY for the second quarter of 2022 and achieve a 65–70% revenue growth for the full year of 2022. The Company will closely monitor the development of the outbreak and will provide business updates as and when appropriate. The abovementioned operating performance forecast for the second quarter of 2022 is made based on the current order backlog of the Company. In addition, such operating performance forecast is subject to various prerequisites, including the continued stabilization or improvement of the COVID-19 global pandemic (especially the pandemic in Shanghai receiving effective control by the end of April 2022), the stable development of the global pharmaceutical industry and the stability of the international trade environment and regulatory environment of the countries where the main operations of the Company are located. Further, such operating performance forecast does not constitute a profit forecast by the management of the Company for the second quarter of 2022 nor a substantive undertaking by the Company to investors. Its realization is subject to various factors including but not limited to changes in internal and external environment, where greater uncertainty exists.

IV. Information about shareholders

1. Total number of ordinary shareholders, total number of preference shareholders with voting rights restored and shareholdings of the top 10 shareholders as at the end of the Reporting Period

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period	206,649
Total number of preference shareholders with voting rights restored at the end of the Reporting Period (if any)	Nil

Shareholdings of top 10 Shareholders

Full name of shareholder	Nature of shareholders	Number of Shares held as at the end of the Reporting Period	Percentage (%)	Number of Shares subject to trading restrictions	Pledged, marked or frozen Shares	
					Status	Number
HKSCC NOMINEES LIMITED ^(Note 1)	Overseas legal entity	392,128,463	13.2663	0	Unknown	0
G&C VI Limited	Overseas legal entity	190,512,000	6.4453	0	Nil	0
Hong Kong Securities Clearing Company Limited ^(Note 2)	Overseas legal entity	175,555,519	5.9393	0	Unknown	0
SUMMER BLOOM INVESTMENTS (I) PTE. LTD.	Overseas legal entity	159,160,073	5.3846	0	Nil	0
G&C IV Hong Kong Limited	Overseas legal entity	139,319,309	4.7134	0	Nil	0
G&C V Limited	Overseas legal entity	97,349,515	3.2935	0	Nil	0
Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership) (北京中民銀孚投資管理有限公司—嘉興宇祥投資合夥企業 (有限合夥))	Other	87,074,568	2.9459	0	Nil	0
Industrial and Commercial Bank of China Limited — China-Europe Medical and Health Hybrid Securities Investment Fund (中國工商銀行股份有限公司 — 中歐醫療健康混合型證券投資基金)	Other	59,327,580	2.0071	0	Nil	0
G&C VII Limited	Overseas legal entity	50,415,120	1.7056	0	Nil	0
Shanghai Houshen Investment Center (Limited Partnership) (上海厚燊投資中心 (有限合夥))	Other	45,735,228	1.5473	0	Nil	0

Shareholdings of top 10 holders of Shares not subject to trading restrictions

Name of shareholder	Number of Shares not subject to trading restrictions	Class and number of Shares	
		Class	Number
HKSCC NOMINEES LIMITED ^(Note 1)	392,128,463	Overseas-listed foreign shares	392,128,463
G&C VI Limited	190,512,000	RMB-denominated ordinary shares	190,512,000
Hong Kong Securities Clearing Company Limited ^(Note 2)	175,555,519	RMB-denominated ordinary shares	175,555,519
SUMMER BLOOM INVESTMENTS (I) PTE. LTD.	159,160,073	RMB-denominated ordinary shares	159,160,073
G&C IV Hong Kong Limited	139,319,309	RMB-denominated ordinary shares	139,319,309
G&C V Limited	97,349,515	RMB-denominated ordinary shares	97,349,515
Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaying Yuxiang Investment Partnership (Limited Partnership) (北京中民銀孚投資管理有限公司—嘉興宇祥投資合夥企業(有限合夥))	87,074,568	RMB-denominated ordinary shares	87,074,568
Industrial and Commercial Bank of China Limited — China-Europe Medical and Health Hybrid Securities Investment Fund (中國工商銀行股份有限公司 — 中歐醫療健康混合型證券投資基金)	59,327,580	RMB-denominated ordinary shares	59,327,580
G&C VII Limited	50,415,120	RMB-denominated ordinary shares	50,415,120
Shanghai Houshen Investment Center (Limited Partnership) (上海厚燊投資中心(有限合夥))	45,735,228	RMB-denominated ordinary shares	45,735,228
Description of connected relationships or concerted actions of the above shareholders	G&C VI Limited, G&C IV Hong Kong Limited, G&C V Limited, G&C VII Limited, and Shanghai Houshen Investment Center (Limited Partnership) being part of the top 10 shareholders of the Company, are under the control of Ge Li.		
The participation of top 10 shareholders and top 10 shareholders holding Shares not subject to trading restrictions in financing, financial notes and financial institution backed securities business (if any)	Not applicable		

Note 1: HKSCC NOMINEES LIMITED holds shares on behalf of its multiple clients.

Note 2: Hong Kong Securities Clearing Company Limited is the nominee holder of the RMB denominated ordinary shares under the Shanghai-Hong Kong Stock Connect.

V. Other reminders

Other important information about the Company's operating conditions during the Reporting Period that investors need to be reminded of and pay attention to.

Applicable Not applicable

VI. Quarterly financial statements

1. Type of auditor's opinion

Applicable Not applicable

2. Financial statements

Consolidated Balance Sheet

As at March 31, 2022

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB Type of audit: Unaudited

Item	As at March 31, 2022	As at December 31, 2021
Current Assets:		
Bank balances and cash	7,026,897,217.80	8,238,772,782.53
Financial assets held for trading	276,257,866.61	527,288,380.38
Derivative financial assets	296,320,626.37	229,142,186.76
Note receivables	25,000,000.00	48,000,000.00
Trade receivables	6,389,675,898.80	4,619,550,091.65
Prepayments	346,731,590.56	302,910,091.83
Other receivables	315,133,942.40	339,579,823.47
Including: Interest receivables	—	38,280.82
Dividend receivables	—	—
Inventories	6,414,769,393.91	5,905,005,712.92
Contract assets	843,762,287.51	773,432,779.63
Other current assets	1,105,076,328.50	1,001,966,753.16
Total Current Assets	23,039,625,152.46	21,985,648,602.33
Non-current Assets:		
Long-term equity investments	581,773,664.02	678,304,556.75
Other non-current financial assets	8,564,536,277.92	8,714,098,195.97
Fixed assets	9,038,061,513.70	8,553,875,239.51
Construction in progress	6,748,555,788.32	5,771,792,447.77
Productive biological assets	824,031,000.00	733,510,000.00
Right-of-use assets	1,120,731,197.55	1,069,566,509.12
Intangible assets	1,631,994,944.19	1,599,754,747.41
Goodwill	1,906,670,594.55	1,925,563,131.98
Long-term deferred expenditures	1,520,858,650.93	1,539,454,173.75
Deferred tax assets	418,716,567.48	389,846,300.63
Other non-current assets	2,187,375,523.57	2,165,974,478.81
Total Non-current Assets	34,543,305,722.23	33,141,739,781.70
Total Assets	57,582,930,874.69	55,127,388,384.03

Item	As at March 31, 2022	As at December 31, 2021
Current Liabilities:		
Short-term borrowings	2,692,723,110.21	2,261,479,950.00
Financial liabilities held for trading	—	—
Derivative financial liabilities	—	3,651,608.46
Note payables	—	—
Trade payables	2,437,648,664.44	1,931,006,166.97
Contract liabilities	3,295,966,556.79	2,986,378,875.46
Payroll payables	982,089,603.96	1,580,451,651.57
Tax payables	881,178,451.81	536,009,384.72
Other payables	2,919,694,218.00	3,289,192,625.17
Including: Interest payables	1,847,744.24	1,337,744.33
Dividend payables	—	—
Non-current liabilities due within one year	386,026,572.30	396,423,607.05
Other current liabilities	—	—
Total Current Liabilities	13,595,327,177.51	12,984,593,869.40
Non-current Liabilities:		
Bond payables	606,284,876.93	607,140,031.37
Including: Preference shares	—	—
Perpetual bonds	—	—
Rental liabilities	1,094,448,876.98	1,018,978,731.37
Deferred income	763,788,956.06	770,600,758.25
Deferred tax liabilities	299,942,129.62	324,125,305.36
Other non-current liabilities	575,362,049.06	664,487,072.47
Total Non-current Liabilities	3,339,826,888.65	3,385,331,898.82
Total Liabilities	16,935,154,066.16	16,369,925,768.22
Owners' Equity (or Shareholders' Equity):		
Paid-in capital (or share capital)	2,955,815,989.00	2,955,826,899.00
Capital reserve	25,959,457,118.10	25,731,889,443.00
Less: Treasury shares	2,448,221,320.92	2,459,221,426.68
Other comprehensive income	-279,949,570.42	-271,422,544.97
Special reserve	—	—
Surplus reserve	408,358,883.50	408,358,883.50
Undistributed profit	13,769,025,721.87	12,126,078,376.75

Item	As at March 31, 2022	As at December 31, 2021
Total Equity (or Shareholders' Equity) attributable to owners of the Company	40,364,486,821.13	38,491,509,630.60
Minority interests	283,289,987.40	265,952,985.21
Total Owners' Equity (or Shareholders' Equity)	40,647,776,808.53	38,757,462,615.81
Total Liabilities and Owners' Equity (or Shareholders' Equity)	57,582,930,874.69	55,127,388,384.03

Legal Representative:	Ge Li
Chief Financial Officer:	Ming Shi
Director of the Accounting Department:	Jin Sun

Consolidated Income Statement

January to March 2022

Prepared by: WuXi AppTec Co., Ltd

Unit: RMB Type of audit: Unaudited

Item	First quarter of 2022	First quarter of 2021
I. Total revenue	8,474,419,333.59	4,950,479,646.73
Including: Revenue	8,474,419,333.59	4,950,479,646.73
II. Total cost	6,529,312,349.78	3,996,298,821.50
Including: Cost	5,441,326,127.95	3,113,892,231.21
Taxes and surcharges	22,290,202.83	11,148,414.98
Selling expenses	173,175,682.02	158,557,564.92
Administrative expenses	602,622,005.65	475,746,512.10
Research and development expenses	280,042,477.39	204,576,017.34
Finance expenses	9,855,853.94	32,378,080.95
Including: Interest expense	14,575,523.98	20,927,338.15
Interest income	27,946,244.55	44,790,090.79
Add: Other income	58,453,423.54	61,754,773.61
Investment gains (“-” indicating loss)	44,047,206.47	483,772,891.12
Including: Gains from investments in associates and joint ventures	-93,893,170.74	-28,416,448.00
Gains from changes in fair value (“-” indicating loss)	6,151,664.14	211,808,047.02
Credit impairment losses (“-” indicating loss)	-36,355,477.85	-15,064,756.44
Assets impairment losses (“-” indicating loss)	-9,916,958.88	3,549,126.28
Gains on assets disposal (“-” indicating loss)	-2,527,111.99	-2,461,340.63
III. Operating profit (“-” indicating loss)	2,004,959,729.24	1,697,539,566.19
Add: Non-operating income	1,684,793.24	3,411,377.51
Less: Non-operating expenses	7,974,615.23	5,057,146.59

Item	First quarter of 2022	First quarter of 2021
IV. Total profit (“-” indicating total loss)	1,998,669,907.25	1,695,893,797.11
Less: Income tax expenses	342,719,385.36	188,789,073.54
V. Net profit (“-” indicating net loss)	1,655,950,521.89	1,507,104,723.57
(I) Classified by continuity of operations		
1. Net profit from continuing operations (“-” indicating net loss)	1,655,950,521.89	1,507,104,723.57
2. Net profit from discontinued operations (“-” indicating net loss)	—	—
(II) Classified by ownership		
1. Net profit attributable to the owners of the Company (“-” indicating net loss)	1,642,947,345.12	1,499,805,405.26
2. Profit attributable to non-controlling interests (“-” indicating net loss)	13,003,176.77	7,299,318.31
VI. Other comprehensive income, net of tax	-9,302,502.42	-103,064,283.62
(I) Other comprehensive income attributable to owners of the Company, net of tax	-8,527,025.45	-101,034,221.30
1. Other comprehensive income that will not be reclassified to profit or loss	—	—
2. Other comprehensive income that will be reclassified to profit or loss	-8,527,025.45	-101,034,221.30
(1) Other comprehensive income that will be transferred to profit or loss accounted for using equity method	—	—
(2) Changes in fair value of other debt investments	—	—
(3) Financial assets reclassified to other comprehensive income	—	—
(4) Credit impairment allowance of other debt investments	—	—
(5) Cash flow hedging reserve	59,247,344.82	-185,041,087.58
(6) Exchange difference on translation of foreign financial statements	-67,774,370.27	84,006,866.28
(7) Others	—	—

Item	First quarter of 2022	First quarter of 2021
(II) Other comprehensive income attributable to non-controlling interests, net of tax	-775,476.97	-2,030,062.32
VII. Total comprehensive income	1,646,648,019.47	1,404,040,439.95
(I) Total comprehensive income attributable to owners of the Company	1,634,420,319.67	1,398,771,183.96
(II) Total comprehensive income attributable to non-controlling interests	12,227,699.80	5,269,255.99
VIII. Earnings per share:		
(I) Basic earnings per share (RMB per share)	0.56	0.52
(II) Diluted earnings per share (RMB per share)	0.53	0.51

For the business combination involving enterprises under common control during the Reporting Period, realised net profit of the merged parties before the merger was nil (corresponding period of the previous year: nil).

Legal Representative:	Ge Li
Chief Financial Officer:	Ming Shi
Director of the Accounting Department:	Jin Sun

Consolidated Statement of Cash Flows

January to March 2022

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB Type of audit: Unaudited

Item	First quarter of 2022	First quarter of 2021
I. Cash flow from operating activities:		
Cash received from sale of goods or rendering of services	7,347,858,876.59	4,817,465,850.56
Refunds of taxes and surcharges	210,989,462.65	210,175,344.52
Cash received relating to other operating activities	89,894,787.87	85,250,543.68
Sub-total of cash inflow from operating activities	7,648,743,127.11	5,112,891,738.76
Cash paid for purchasing goods and receiving services	3,605,011,698.68	1,918,918,951.82
Cash paid to and on behalf of employees	2,792,682,606.48	2,114,896,938.06
Payments of taxes and surcharges	192,630,925.82	168,868,139.16
Cash paid relating to other operating activities	560,948,842.63	241,427,482.30
Sub-total of cash outflow from operating activities	7,151,274,073.61	4,444,111,511.34
Net cash flow generated from operating activities	497,469,053.50	668,780,227.42
II. Cash flow from investing activities:		
Cash received from disposal of investments	466,903,546.42	2,233,228,663.76
Cash received from return on investments	9,385,554.80	48,468,810.90
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	459,285.30	4,434,588.71
Net cash received from disposal of subsidiaries and other business entities	—	—
Cash received relating to other investing activities	—	—
Sub-total of cash inflow from investing activities	476,748,386.52	2,286,132,063.37
Cash paid to acquire fixed assets, intangible assets and other long-term assets	2,207,629,830.98	1,072,487,484.91
Cash paid to acquire investments	259,177,134.06	869,347,127.42

Item	First quarter of 2022	First quarter of 2021
Net cash paid to acquire subsidiaries and other business entities	—	841,578,273.75
Cash paid relating to other investing activities	—	—
Sub-total of cash outflow from investing activities	2,466,806,965.04	2,783,412,886.08
Net cash flow from investing activities	-1,990,058,578.52	-497,280,822.71
III. Cash flow from financing activities:		
Cash received from capital contributions:	5,405,757.26	4,541,320.00
Including: Cash received from capital contribution by minority shareholders of subsidiaries	—	—
Cash received from borrowings	657,351,560.21	413,991,900.00
Cash received relating to other financing activities	—	—
Sub-total of cash inflow from financing activities	662,757,317.47	418,533,220.00
Cash repayments of borrowings	215,474,800.00	118,142,600.00
Cash payments for distribution of dividends, profits or interest expenses	7,267,485.49	9,220,037.36
Including: Dividends and profits paid by subsidiaries to minority shareholders	—	3,400,000.00
Cash paid relating to other financing activities	52,712,481.31	56,951,243.81
Sub-total of cash outflow from financing activities	275,454,766.80	184,313,881.17
Net cash flow generated from financing activities	387,302,550.67	234,219,338.83

Item	First quarter of 2022	First quarter of 2021
IV. Effect of fluctuations in exchange rates on cash and cash equivalents	-43,524,420.10	35,022,627.66
V. Net increase in cash and cash equivalents	-1,148,811,394.45	440,741,371.20
Add: Balance of cash and cash equivalents at the beginning of the period	8,175,335,986.42	10,228,057,054.30
VI. Balance of cash and cash equivalents at the end of the period	7,026,524,591.97	10,668,798,425.50

Legal Representative: Ge Li
Chief Financial Officer: Ming Shi
Director of the Accounting Department: Jin Sun

3. Adjustments on the financial statements at the beginning of the first year of adopting new leasing standards since 2022

Applicable Not applicable

4. **Quarterly condensed consolidated financial statements prepared in accordance with IFRSs**

Consolidated Statement of Profit or Loss and Other Comprehensive Income

January to March 2022

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

	First quarter of 2022	First quarter of 2021
Revenue	8,474,419	4,950,480
Cost of services	<u>(5,459,571)</u>	<u>(3,112,267)</u>
Gross profit	<u>3,014,848</u>	<u>1,838,213</u>
Other income	95,717	106,454
Other gains and losses	118,999	678,972
Impairment losses under expected credit losses (“ECL”) model, net of reversal	(36,355)	(15,065)
Selling and marketing expenses	(173,176)	(158,558)
Administrative expenses	(618,866)	(486,127)
Research and development expenses	<u>(280,042)</u>	<u>(204,576)</u>
Operating profit	<u>2,121,125</u>	<u>1,759,313</u>
Share of loss of associates	(96,227)	(24,363)
Share of profits (loss) of joint ventures	2,333	(4,054)
Finance costs	<u>(28,561)</u>	<u>(35,002)</u>
Profit before tax	<u>1,998,670</u>	<u>1,695,894</u>
Income tax expense	<u>(342,719)</u>	<u>(188,789)</u>
Profit for the period	<u><u>1,655,951</u></u>	<u><u>1,507,105</u></u>

	First quarter of 2022	First quarter of 2021
Other comprehensive income (expense) for the period		
<i>Items that may be reclassified subsequently to profit or loss:</i>		
Exchange differences on translation of financial statements of foreign operations	(69,509)	83,955
Fair value gain (losses) on hedging instrument designated in cash flow hedges	<u>60,206</u>	<u>(187,018)</u>
Other comprehensive expense for the period, net of income tax	<u>(9,303)</u>	<u>(103,064)</u>
Total comprehensive income for the period	<u>1,646,648</u>	<u>1,404,040</u>
Profit for the period attributable to:		
Owners of the Company	1,642,947	1,499,806
Non-controlling interests	<u>13,004</u>	<u>7,299</u>
	<u>1,655,951</u>	<u>1,507,105</u>
Total comprehensive income for the period attributable to:		
Owners of the Company	1,634,420	1,398,771
Non-controlling interests	<u>12,228</u>	<u>5,269</u>
	<u>1,646,648</u>	<u>1,404,040</u>
Earnings per share (expressed in RMB per share)		
— Basic	<u>0.56</u>	<u>0.52</u>
— Diluted	<u>0.53</u>	<u>0.51</u>

Consolidated Statement of Financial Position

As at March 31, 2022

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

	As at March 31, 2022	As at December 31, 2021
Non-current Assets		
Property, plant and equipment	17,293,813	15,848,703
Right of use assets	1,883,163	1,779,500
Goodwill	1,906,671	1,925,563
Other intangible assets	869,563	889,822
Interest in associates	520,616	619,382
Interest in joint ventures	61,157	58,923
Financial assets at fair value through profit or loss ("FVTPL")	8,564,536	8,714,098
Deferred tax assets	418,717	389,846
Other non-current assets	2,201,039	2,182,393
Biological assets	824,031	733,510
Total Non-current Assets	34,543,306	33,141,740
Current Assets		
Inventories	4,945,964	4,554,577
Trade and other receivables	7,860,876	5,968,471
Contract assets	843,762	773,433
Contract costs	596,958	594,912
Biological assets	871,848	755,517
Income tax recoverable	225	225
Financial assets at FVTPL	276,258	527,288
Amounts due from related parties	320,515	343,310
Derivative financial instruments	296,321	229,142
Pledged bank deposits	373	63,437
Bank balances and cash	7,026,525	8,175,336
Total Current Assets	23,039,625	21,985,648
Total Assets	57,582,931	55,127,388

	As at March 31, 2022	As at December 31, 2021
Current Liabilities		
Trade and other payables	6,479,147	6,855,964
Income tax payables	724,600	459,256
Amounts due to related parties	16,863	21,439
Borrowings	2,692,723	2,261,480
Lease liabilities	208,078	220,183
Derivative financial instruments	—	3,652
Contract liabilities	3,295,967	2,986,379
Other current liabilities	177,949	176,241
	<hr/>	<hr/>
Total Current Liabilities	13,595,327	12,984,594
	<hr/>	<hr/>
Non-current Liabilities		
Deferred tax liabilities	299,942	324,125
Deferred income	763,789	770,601
Lease liabilities	1,094,449	1,018,979
Convertible bonds — debt component	606,285	607,140
Convertible bonds — derivative component	567,852	657,317
Other long-term liabilities	7,510	7,170
	<hr/>	<hr/>
Total Non-current Liabilities	3,339,827	3,385,332
	<hr/>	<hr/>
Total Liabilities	16,935,154	16,369,926
	<hr/>	<hr/>
Capital and Reserves		
Share capital	2,955,816	2,955,827
Reserves	37,408,671	35,535,682
	<hr/>	<hr/>
Equity attributable to owners of the Company	40,364,487	38,491,509
Non-controlling interests	283,290	265,953
	<hr/>	<hr/>
Total Equity	40,647,777	38,757,462
	<hr/> <hr/>	<hr/> <hr/>

Consolidated Statement of Cash Flows

January to March 2022

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

	First quarter of 2022	First quarter of 2021
Net cash from operating activities	417,230	648,781
Investing activities		
Interests received	7,340	26,988
Proceeds from disposal of financial assets at FVTPL	463,374	2,933,229
Purchase of financial assets at FVTPL	(259,177)	(847,732)
Purchase of other non-current assets	—	(700,000)
Proceeds from disposal of other intangible assets	307	324
Proceeds from disposal of property, plant and equipment	152	4,110
Acquisition of interests in associates/investment in associates	—	(11,250)
Purchase of property, plant and equipment	(2,150,670)	(1,055,488)
Purchases of right-of-use assets	(55,723)	—
Purchase of other intangible assets	(1,237)	(16,999)
Withdrawal of pledged bank deposits	63,064	770
Net cash outflow on acquisition of subsidiaries	—	(841,578)
Dividends received from associates	—	9,781
Dividends received from financial assets at FVTPL	12,915	38,688
Payment for forward contracts	—	(10,365)
Payments of lease deposits	(414)	(8,560)
R&D grants and others received related to assets	10,249	800
Net cash used in investing activities	(1,909,820)	(477,282)

	First quarter of 2022	First quarter of 2021
Financing activities		
Payment of dividends	—	(3,400)
New borrowings raised	657,352	413,992
Repayments of borrowings	(215,475)	(118,143)
Acquisition of part of interests in a subsidiary from non-controlling shareholders	—	(13,470)
Net Proceeds from exercise of stock option	5,406	4,541
Interests paid	(7,267)	(5,820)
Repayments of lease liabilities	(52,713)	(42,163)
Issue cost paid	—	(1,318)
	<hr/>	<hr/>
Net cash from financing activities	387,303	234,219
	<hr/>	<hr/>
Net (decrease)increase in cash and cash equivalents	(1,105,287)	405,718
	<hr/>	<hr/>
Cash and cash equivalents at the beginning of the period	8,175,336	10,228,057
Effects of exchange rate changes	(43,524)	35,023
	<hr/>	<hr/>
Cash and cash equivalents at the end of the period	<u>7,026,525</u>	<u>10,668,798</u>

5. Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company

Unit: RMB'000 Type of audit: Unaudited

	First quarter of 2022	First quarter of 2021
Net profit attributable to the owners of the Company	1,642,947	1,499,806
Add:		
Share-based compensation expenses	180,469	126,281
Issuance expenses of convertible bonds	413	1,004
Fair value (gain)/loss from derivative component of convertible bonds	(82,795)	451,091
Foreign exchange related losses	5,821	35,514
Amortization of acquired intangible assets from merge and acquisition	14,463	11,245
	<u>1,761,319</u>	<u>2,124,940</u>
Non-IFRS net profit attributable to the owners of the Company	1,761,319	2,124,940
Add:		
Realized and unrealized losses/(gains) from venture investments	293,660	(1,024,326)
Realized and unrealized share of (gains)/losses from joint ventures	(2,333)	4,054
	<u>(2,333)</u>	<u>4,054</u>
Adjusted non-IFRS net profit attributable to the owners of the Company	<u>2,052,645</u>	<u>1,104,668</u>

Notes:

- (1) Any discrepancies between the total shown and the sum of the amounts listed in the above table are due to rounding.
- (2) The Company has adjusted the scope of the foreign exchange related gains or losses in the calculation of non-IFRS measures, by adjusting only the gains or losses that the management believes are irrelevant to the core business. The comparative financial figures for the comparable periods has been adjusted to reflect the change of scope.